Krystal BiotechKRYS
KRYS
About: Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Employees: 275
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
72% more call options, than puts
Call options by funds: $63.3M | Put options by funds: $36.8M
0% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]
2% less repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 96
1.04% less ownership
Funds ownership: 97.58% [Q3] → 96.55% (-1.04%) [Q4]
6% less funds holding
Funds holding: 279 [Q3] → 262 (-17) [Q4]
15% less capital invested
Capital invested by funds: $5.1B [Q3] → $4.35B (-$753M) [Q4]
24% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 50
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$215
28%
upside
Avg. target
$223
32%
upside
High target
$245
45%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Jefferies Roger Song 11% 1-year accuracy 2 / 18 met price target | 45%upside $245 | Buy Initiated | 5 Mar 2025 |
HC Wainwright & Co. Joseph Pantginis 15% 1-year accuracy 62 / 415 met price target | 31%upside $221 | Buy Reiterated | 28 Feb 2025 |
Citigroup Yigal Nochomovitz 12% 1-year accuracy 5 / 41 met price target | 28%upside $215 | Neutral Maintained | 20 Feb 2025 |
Cantor Fitzgerald Josh Schimmer 20% 1-year accuracy 11 / 54 met price target | 28%upside $215 | Overweight Reiterated | 20 Feb 2025 |
Chardan Capital Geulah Livshits 7% 1-year accuracy 4 / 60 met price target | 29%upside $218 | Buy Maintained | 20 Feb 2025 |
Financial journalist opinion
Based on 4 articles about KRYS published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well as launching and commercializing leading brands, including BOTOX®, one of the most widely recognized global brands. Mr. Forth has also served as a valuable contributor on Jeune's board of directors since February 2021.
Neutral
Zacks Investment Research
1 week ago
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
Positive
Seeking Alpha
3 weeks ago
Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK
Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation, potentially boosting its global market presence and valuation. Despite KRYS's premium valuation, its growth potential, strong financials, and first-mover advantage justify the market's appraisal, with a fair value estimate of $175-$185 per share. Key risks include regulatory setbacks, reimbursement issues, competition from Abeona's EB-101, and high operational expenses, which could impact short-term valuation and cash flow.
Positive
Zacks Investment Research
4 weeks ago
Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Positive
Zacks Investment Research
1 month ago
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
1 month ago
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?
KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
Positive
Zacks Investment Research
1 month ago
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?
KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
Positive
Zacks Investment Research
1 month ago
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.
Neutral
GlobeNewsWire
1 month ago
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA's) announcement that its Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the European Commission (EC) to approve VYJUVEK® (beremagene geperpavec-svdt, or B-VEC) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. The CHMP's positive opinion includes support for administration of VYJUVEK in either a health care setting (e.g.
Positive
Zacks Investment Research
1 month ago
Why Krystal Biotech (KRYS) Might be Well Poised for a Surge
Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Charts implemented using Lightweight Charts™